Roivant Sciences (NASDAQ:ROIV) Director Sells $21,276,622.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock in a transaction on Friday, June 26th. The shares were sold at an average price of $34.00, for a total transaction of $21,276,622.00. Following the completion of the sale, the director directly owned 14,501,546 shares of the company’s stock, valued at approximately $493,052,564. The trade was a 4.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The stock was sold at an average price of $35.28, for a total value of $436,766.40.
• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00.

Roivant Sciences Price Performance

ROIV opened at $35.13 on Friday. The company’s 50-day moving average is $30.12 and its 200 day moving average is $27.21. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $35.90. The firm has a market capitalization of $25.27 billion, a P/E ratio of -58.55 and a beta of 1.11.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period in the prior year, the firm posted ($0.29) EPS. On average, equities research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Versant Capital Management Inc raised its holdings in Roivant Sciences by 13.9% in the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock worth $141,000 after buying an additional 487 shares during the last quarter. Pacer Advisors Inc. grew its holdings in shares of Roivant Sciences by 37.1% in the first quarter. Pacer Advisors Inc. now owns 96,303 shares of the company’s stock worth $2,668,000 after acquiring an additional 26,044 shares during the period. Empowered Funds LLC grew its stake in shares of Roivant Sciences by 1,468.5% during the 1st quarter. Empowered Funds LLC now owns 285,915 shares of the company’s stock valued at $7,920,000 after purchasing an additional 267,686 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Roivant Sciences during the first quarter valued at approximately $3,550,000. Finally, Parallel Advisors LLC increased its stake in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of analyst reports. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. TD Cowen increased their price objective on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Guggenheim raised their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.